Matthew Barcus
Stock Analyst at Chardan Capital
(2.44)
# 2,548
Out of 5,044 analysts
21
Total ratings
25%
Success rate
26.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $3.77 | +165.25% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $70.00 | -61.43% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.82 | +753.66% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $21.98 | +45.59% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $0.58 | +37,635.85% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $4.24 | +112.26% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $16.39 | -51.19% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $3.77
Upside: +165.25%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $70.00
Upside: -61.43%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.82
Upside: +753.66%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $21.98
Upside: +45.59%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $0.58
Upside: +37,635.85%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $4.24
Upside: +112.26%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $16.39
Upside: -51.19%